Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
G Fountzilas, U Dafni, H Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T Amaral, M Ottaviano, A Arance, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
L Kandolf Sekulovic, J Guo, S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2007
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
G Fountzilas, U Dafni, H Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 23, 2023
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
E Livingstone, H Gogas, L Kandolf-Sekulovic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2024
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T Amaral, M Ottaviano, A Arance, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
December 16, 2020
Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries
L Kandolf-Sekulovic, K Peris, A Stratigos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
L Kandolf Sekulovic, J Guo, S Agarwala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
Page
of 8